

Overview


Tumor Infiltrated Lymphocytes (TILs) in vitro expansion are innovative T Cell therapies in the field of immunotherapy with increasing promise against cancer.

TILs Expansion and Killing Assays

At Vivia Biotech we have **access to primary samples** from patients diagnosed with **hematological malignancies and several solid tumors** indications. From those patients samples we are able to **activate and expand TILs** for ex vivo testing, which could be **directly shipped from Vivia to your facilities** or applied in **functional assays**, such as **tumor killing assays**, potentiated by your compounds.

Click  to learn more

Click  for custom assays in solid tumors

Click  for custom assays in hematological malignancies





Figure 1. Vivia Rapid TILs Expansion protocol is based on clinically validated TILs expansion method (Rosemberg et al 2012 & Iovance)

Overview

Tumor Infiltrated Lymphocytes (TILs) in vitro expansion are innovative T Cell therapies in the field of immunotherapy with increasing promise against cancer.

Click  to learn more

Click  for custom assays in solid tumors

Click  for custom assays in hematological malignancies

- We have access to various patient solid tumor indications: Colorectal, Ovarian, Pancreas, Liver, Lung carcinomas, etc.
- TILs are phenotypically characterized at baseline and during expansion.
- Exhaustion markers can be explored.
- The rapid expansion of TILs provides number and activation profiles suitable for custom in vitro experimentation with target tumor cells.
- Expanded TILs from different pathologies are stored in a cryobank available for:
 - Directly shipment from Vivia
 - Functional assays, such as tumor killing assays against any solid tumor cell lines, potentiated by clients' compounds.




Figure 2. Example of functional tumor killing assay combining ovarian expanded TILs and pancreatic tumor cell line, at different effector-target ratios.

**“If you are planning to attend ESMO in Madrid in October,
we would be delighted to meet with you at your earliest convenience”**
